SIRVIVIN AND ITS ROLE IN MALIGNANT TUMORS

Cover Page

Cite item

Full Text

Abstract

During the last years study of survivin and other proteins from inhibitors of apoptosis family role in malignant transformation and tumor progression draws great attention. Survivin is expressed during the embryogenesis and is practically silent in all kinds of differentiated cells of adult organisms, but restarts its expression in the diversity of transformed cells types. Numerous attempts were made in order to use this protein as a diagnostic or prognostic marker as well as a target for anticancer therapy. Very recently published data evidences on survivin direct participation in the process of metastasis, what makes its study especially essential. Present review summarizes the modern knowledge, concerning the survivin structure and expression in human tumors. Special attention is drawn to its importance in different sarcomas development

About the authors

Российский онкологический научный центр им. Н.Н. Блохина РАМН

Author for correspondence.
Email: ovkovaleva@gmail.com
Russian Federation

Российский онкологический научный центр им. Н.Н. Блохина РАМН

Russian Federation

Российский онкологический научный центр им. Н.Н. Блохина РАМН

Russian Federation

O. V. Kovaleva

N.N. Blokhin Russian Cancer Research Center Russian Academy of Medical Sciences

Russian Federation

A. N. Shneyderman

N.N. Blokhin Russian Cancer Research Center Russian Academy of Medical Sciences

Russian Federation

E. M. Tchevkina

N.N. Blokhin Russian Cancer Research Center Russian Academy of Medical Sciences

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 ., ., ., Kovaleva O.V., Shneyderman A.N., Tchevkina E.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-66671 от  09.11.2009.